Document is current

Article History

Received: 3 January 2018

Accepted: 9 March 2018

First Online: 5 April 2018

Ethics approval and consent to participate

: The AID-registry has been approved by the ethics committees and the data protection responsible at the University of Duisburg-Essen and Muenster, as well as the Medical Association Nordrhein in Duesseldorf. Parents, children between 9 and 13 years of age and young patients aged ≥ 14 years provide informed consent. All old and new documents of the ethic committees are saved on our homepage.

: Not applicable.

: E Lainka has received consulting fees, speaking fees, and/or honoraria from Novartis (less than $10,000 each) and research support from Sobi. J-P Haas has received research support from Novartis and Pfizer. T Kallinich has received consulting fees, speaking fees, and/or honoraria from Bristol-Myers-Squibb, CSL, Novartis and Roche (less than $10,000 each) and research support from Novartis. E Weißbarth-Riedel has received consulting fees, speaking fees, and/or honoraria from Novartis (less than $10,000 each). H Wittkowski has received consulting fees, speaking fees, and/or honoraria from Novartis (less than $10,000 each). G Horneff has received honoraria from Abbvie, Novartis, Pfizer and Roche-Chugai (less than $10,000 each) and research support from Abbvie, Novartis, Pfizer and Roche-Chugai. D Foell has received honoraria from Novartis, Pfizer, Roche-Chugai and Sobi (less than $10,000 each) and research support from Novartis and Pfizer. M Bielak, E Husmann, N Weyandt, J Klotsche, E Lilienthal, T Niehues, K Tenbrock, G Heubner, T Lutz and R Berendes do not have a competing interest. U Neudorf has received speaking fees from Pfizer, Abbvie (less than $10,000 each) und research support from Chugai (more than $10,000). B Hügle has received speaking fees and/or honoraria from Novartis and Roche (less than $10,000 each) and two unrestricted research grants from Novartis. PT Oommen has received consulting fees, speaking fees, and/or honoria from Novartis and CSL Behring (less than $5,000 each).

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.